Shares of Qiagen NV (NYSE:QGEN) have been assigned an average rating of “Hold” from the fourteen ratings firms that are covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $39.33.
QGEN has been the subject of a number of recent research reports. Deutsche Bank reissued a “buy” rating on shares of Qiagen in a research note on Tuesday, October 30th. Zacks Investment Research reissued a “hold” rating on shares of Qiagen in a research note on Wednesday, November 14th. BidaskClub upgraded shares of Qiagen from a “sell” rating to a “hold” rating in a report on Friday, November 2nd. Morgan Stanley raised their target price on shares of Qiagen from $39.00 to $41.00 and gave the stock an “overweight” rating in a report on Wednesday, October 31st. Finally, Commerzbank restated a “buy” rating on shares of Qiagen in a report on Monday, October 22nd.
QGEN traded down $0.38 during trading on Wednesday, hitting $36.10. 31,370 shares of the company traded hands, compared to its average volume of 1,560,063. The stock has a market capitalization of $8.26 billion, a price-to-earnings ratio of 28.48, a PEG ratio of 2.16 and a beta of 0.92. Qiagen has a 1 year low of $31.01 and a 1 year high of $39.45. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.25 and a current ratio of 1.37.
Qiagen (NYSE:QGEN) last posted its earnings results on Monday, October 29th. The company reported $0.35 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.33 by $0.02. The company had revenue of $377.91 million during the quarter, compared to analysts’ expectations of $382.16 million. Qiagen had a net margin of 6.00% and a return on equity of 12.52%. On average, equities research analysts forecast that Qiagen will post 1.33 earnings per share for the current year.
Several hedge funds have recently bought and sold shares of QGEN. Morgan Stanley raised its position in shares of Qiagen by 16.3% during the 3rd quarter. Morgan Stanley now owns 1,468,052 shares of the company’s stock valued at $55,611,000 after acquiring an additional 205,698 shares in the last quarter. Vanguard Group Inc raised its position in shares of Qiagen by 2.0% during the 3rd quarter. Vanguard Group Inc now owns 6,627,163 shares of the company’s stock valued at $251,037,000 after acquiring an additional 128,125 shares in the last quarter. Finally, State of Alaska Department of Revenue raised its position in shares of Qiagen by 2.0% during the 4th quarter. State of Alaska Department of Revenue now owns 23,547 shares of the company’s stock valued at $811,000 after acquiring an additional 463 shares in the last quarter. 62.73% of the stock is currently owned by institutional investors and hedge funds.
Qiagen Company Profile
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Further Reading: Debt-To-Equity Ratio
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.